Figure 2.
Detection of the CRBN exon 10 splicing isoform from CD138+ purified cells from MM samples. The MM samples collected at the different stages, including newly diagnosed and untreated, relapsed from treatment containing IMiDs and end-stage, were run on the NanoString panel with the newly designed CRBN_5 probe. The ratio of the normalized counts detected by CRBN_5 to the normalized counts detected by total CRBN probe, CRBN_2 was calculated. (A) The percentage of samples with low ratio (<20%) and high ratio (>20%) in the sample harvested at different stages was demonstrated. (B) The ratio of exon 10 isoform to total CRBN statistically trended higher (by Wilcoxon rank sum test) in the samples from IMiD-resistant patients (relapse and end stage) than in the samples from IMiD-sensitive patients (NDMM). NDMM = newly diagnosed multiple myeloma.

Detection of the CRBN exon 10 splicing isoform from CD138+ purified cells from MM samples. The MM samples collected at the different stages, including newly diagnosed and untreated, relapsed from treatment containing IMiDs and end-stage, were run on the NanoString panel with the newly designed CRBN_5 probe. The ratio of the normalized counts detected by CRBN_5 to the normalized counts detected by total CRBN probe, CRBN_2 was calculated. (A) The percentage of samples with low ratio (<20%) and high ratio (>20%) in the sample harvested at different stages was demonstrated. (B) The ratio of exon 10 isoform to total CRBN statistically trended higher (by Wilcoxon rank sum test) in the samples from IMiD-resistant patients (relapse and end stage) than in the samples from IMiD-sensitive patients (NDMM). NDMM = newly diagnosed multiple myeloma.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal